SEC Tracker
Get the app

8-KIOVA

Iovance Biotherapeutics reports record third quarter 2026 revenue

The third quarter 2026 revenue was ~$122 million, an increase of ~80% from ~$67 million in 3Q25 and ~22% from ~$99 million in 2Q26.1

By SEC Tracker ·

Iovance BiotherapeuticsCIK 1425205Form 8-KFiled Nov 5, 2026, 7:06 AM ET0001104659-26-123030Read the filing on SEC.gov →

U.S. Amtagvi revenue was ~$102 million, up ~77% from 3Q25 and ~12% from 2Q26.2 Gross margin was ~60%, compared to 56% in 2Q26.3

The company reported a 24.6% objective response rate (ORR) in 69 patients with non-squamous metastatic non-small-cell lung cancer (mNSCLC) and a 59.1% ORR in a biomarker-selected mNSCLC subgroup.4 A 55.6% ORR was also reported in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS).5

Iovance plans to submit an MAA for Amtagvi in advanced melanoma to ANVISA in 2027 and resubmit to the European Medicines Agency in 2027.6 The company also reported a 30-day turnaround time for Amtagvi production and a resubmitted MAA for the UK expected to be approved by 1Q27.7

Key facts

Company
Iovance Biotherapeutics (IOVA)
CIK
1425205
Form
8-K
Items
2.02
Filed
Nov 5, 2026, 7:06 AM ET
Accession
0001104659-26-123030

From the EDGAR filing index, not written by AI.

Iovance Biotherapeutics results from its filings

Revenue, net income and cash as tagged in XBRL in the company's 10-Q and 10-K filings, up to this filing. Drawn in code; no figure here is written by AI.

Iovance Biotherapeutics revenue and net income by quarterRevenueNet income$ millionsSource: XBRL in the company's 10-Q and 10-K filings, SEC EDGAR−150−100−50050100150Revenue · Q1 FY25: 49.349.3Net income · Q1 FY25: −116.2−116.2Revenue · Q2 FY25: 60.060.0Net income · Q2 FY25: −111.7−111.7Revenue · Q3 FY25: 67.567.5Net income · Q3 FY25: −91.3−91.3Revenue · Q1 FY26: 71.471.4Net income · Q1 FY26: −79.0−79.0Revenue · Q2 FY26: 99.399.3Net income · Q2 FY26: −47.3−47.3Revenue · Q3 FY26: 121.5121.5Net income · Q3 FY26: −22.3−22.3Q1 FY25Q2 FY25Q3 FY25Q1 FY26Q2 FY26Q3 FY26
Iovance Biotherapeutics cash at period end$ millionsSource: XBRL in the company's 10-Q and 10-K filings, SEC EDGAR05010015020057.9FY24Q1 FY25Q2 FY25Q3 FY25FY25Q1 FY26Q2 FY26Q3 FY26Cash · FY24: 115.7Cash · Q1 FY25: 171.7Cash · Q2 FY25: 132.5Cash · Q3 FY25: 158.1Cash · FY25: 163.1Cash · Q1 FY26: 196.5Cash · Q2 FY26: 110.8Cash · Q3 FY26: 57.9
The numbers
PeriodRevenueNet incomeCashFiling
FY24$164.1M−$372.2M$115.7M10-K
Q1 FY25$49.3M−$116.2M$171.7M10-Q
Q2 FY25$60.0M−$111.7M$132.5M10-Q
Q3 FY25$67.5M−$91.3M$158.1M10-Q
FY25$263.5M−$391.0M$163.1M10-K
Q1 FY26$71.4M−$79.0M$196.5M10-Q
Q2 FY26$99.3M−$47.3M$110.8M10-Q
Q3 FY26$121.5M−$22.3M$57.9M10-Q

How often Iovance Biotherapeutics files

Filings per calendar quarter, counted in code from the company's EDGAR filing list. Each bar splits 8-K current reports from other forms; the last bar is the quarter of this filing, counted up to it.

Iovance Biotherapeutics filings per quarter8-KOther formsSource: EDGAR filing list, counted in code05101520258-K · Q1 25: 2Other forms · Q1 25: 188-K · Q2 25: 3Other forms · Q2 25: 188-K · Q3 25: 6Other forms · Q3 25: 118-K · Q4 25: 1Other forms · Q4 25: 78-K · Q1 26: 3Other forms · Q1 26: 198-K · Q2 26: 2Other forms · Q2 26: 238-K · Q3 26: 4Other forms · Q3 26: 118-K · Q4 26: 4Other forms · Q4 26: 320211782225157Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26
Iovance Biotherapeutics filings per quarter
The numbers
QuarterFilings8-K
Q1 25202
Q2 25213
Q3 25176
Q4 2581
Q1 26223
Q2 26252
Q3 26154
Q4 2674

Timeline

The company's filings on EDGAR around this one, newest first. Ownership forms and routine prospectus filings are left out.

  1. Form 8-KThis filing
  2. Form 8-K
  3. Form 10-Q
  4. Form 8-K
  5. Form 8-K
  6. Form 8-K

Get an email when Iovance Biotherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Written with AI from the Iovance Biotherapeutics Form 8-K and checked against it sentence by sentence: each of the 7 numbered sentences opens the passage it comes from. AI can make mistakes. Check the filing. Not investment advice. Not affiliated with the U.S. SEC. Source filing on SEC.gov.

Data on this page was fetched . The filing on SEC.gov is the record.